中国医药
- 网络Medicine;China Medicine
-
中国医药期刊有一篇论文。
There was an article in the Journal of Chinese medicine .
-
中国医药学会有限公司
" Society of Practitioners of Chinese Herbal Medicine Limited , The "
-
基于SVM的中国医药制造企业财务危机预警研究
A Research on Financial Distress Prediction in China 's Pharmaceutical Companies Based on SVM
-
阐述加入WTO后中国医药行业面临的抉择,对我国医药业现状进行分析。
This paper presents analyses on the choices of tile Chinese medical profession after China 's joining WTO , and on the present conditions of the chinese medical profession .
-
随着我国加入WTO,中国医药产业融入国际医药大市场已成为必然趋势,面临的市场竞争将日趋激烈。
It is an inevitable tide that Chinese curatorial industry will merge into the international market after entered the WTO . The competition will be more and more fierce .
-
本文分析了加入WTO将为我国医药业带来的发展机遇和严峻挑战,并提出了中国医药产业应采取的对策,以其为近期我国医药产业的改革和发展提供参考。
This paper presents an analysis on the opportunities and challenges brought to us as a result of the joining of WTO and countermeasures that the Chinese medical industry should adopt .
-
在我国加入WTO之后,各个行业都在发生深刻变化,尤其引人注目的是医药行业。从价值链角度看,中国医药行业正处在剧烈“洗牌”之中。
With the membership of the WTO , China has seen great changes in various sectors , especially in the medicine sector , which is experiencing drastic shuffling in the aspect of chain-value .
-
我国药用植物学研究的回顾与展望中国医药产业CRO的发展前景
PROGRESS ON CHINESE PHARMACEUTICAL BOTANY The Prospect of CRO of Chinese Pharmaceutical Industry
-
综述了中国医药行业的产业特性、市场状况、存在问题,介绍了加入WTO对我国医药行业的影响及我国医药行业的发展趋势。
In this paper , the characteristic , market status and main problem of Chinese medical industry is introduced , and the development currency and the influence of WTO on Chinese medical industry is recommended .
-
中国医药产业CRO的发展前景
The Prospect of CRO of Chinese Pharmaceutical Industry
-
2003年,中国医药开支占总体医疗开支的比例接近45%,而经合组织(OECD)国家这一比例的平均水平仅为15%。
China 's share of pharmaceutical expenditure relative to total health expenditure was nearly 45 per cent in 2003 , compared with an OECD average of about 15 per cent .
-
比如,和黄中国医药科技正在跟阿斯利康(AstraZeneca)与礼来(EliLilly)合作,而百济神州与德国的默克(Merck)进行合作。
China-MediTech , for example , is working with AstraZeneca and Eli Lilly , while BeiGene is paired with Merck of Germany .
-
第二章为文献综述,对生产效率和医药制造业相关研究进行系统梳理。第三章应用PEST框架和SCP模型研究中国医药制造业特征、环境与产业组织。
Chapter two is the literature review of related research works . Chapter three tries to clarify the characteristics , environment and industrial organizations of the pharmaceutical manufacturing industry based on the PEST framework and SCP model .
-
由此关于中国医药产品GMP验证的研究与分析这篇论文旨在通过分析研究先进的、系统的和适应中国国情的高质量的GMP验证流程,提高中国医药产品的安全性和质量。
This paper aims to this on the research and analysis of Chinese medical products GMP validation by advanced systems and high-quality GMP validation process , improve the safety and quality of medical products in China .
-
医疗咨询机构IMS称,过去10年,传统中药在中国医药市场的份额已从1%上升到11%,如今年销售额逾25亿美元。
IMS , the healthcare consultancy , says TCM has grown from 1 per cent to 11 per cent of the Chinese pharmaceuticals market over the past decade , with annual sales today of more than $ 2.5bn .
-
在制药业每天都宣布最新临床试验的大背景下,和黄中国医药科技(HutchisonChinaMediTech)上周宣布已征募病患参加结直肠癌研究的消息,算不上令人振奋。
Amid daily updates from the pharmaceuticals industry on the latest clinical trials , last week 's announcement by Hutchison China MediTech that it had enrolled patients for a study of colorectal cancer was hardly cause for excitement .
-
其核心内容是以跨国医药公司默沙东制药(MSD)为案例,总结默沙东在中国医药行业中,培育核心竞争力的途径和方法。
This is the core of the pharmaceutical multinational pharmaceutical company Merck Sharp & Dohme ( MSD ) as a case , summarized in the Merck pharmaceutical industry in China , cultivating core competitiveness of ways and means .
-
纠正措施包括,新德里希望北京撤销对印度信息技术、宝莱坞(Bollywood)电影以及新鲜食品出口的限制,并增加印度企业在中国医药与IT行业的投资机会。
Among other measures , New Delhi wants Beijing to end restrictions on Indian exports of information technology , Bollywood films and fresh food . It wants greater investment opportunities for Indian companies in sectors such as pharmaceuticals and IT .
-
中国医药行业并购绩效研究
The Study of M & A Performance in Chinese Pharmaceutical Industry
-
中国医药知识产权保护热点问题概述
Overview of the Hotspot Issues in Pharmaceutical IPR Protection in China
-
中国医药产业研究开发战略选择
The Selection of Pharmaceutical Research and Development Strategy in China
-
现在我们在中国医药市场上已达成了相当的规模。
We 've now reached a decent size in China pharmaceutical market .
-
中国医药分销物流变革存在的问题与前景展望
Reform of Medical Distribution and Circulation in China : Problems and Prospect
-
关税降低对于中国医药企业的影响及引申意义
Impact of WTO Free-Trade Tariff Agreement on Chinese Pharmaceutical Firms
-
坚持两个生命观打造中国医药质量大厦
Persevering Two Lives Values and Constructing China Pharmaceutical Quality Building
-
中国医药流通业的现状及发展策略
Present Situation and Developing Strategy of the Pharmaceutical Circulation Enterprises in China
-
中国医药知识产权保护现状分析
A Study on the Present Protection Situation of Pharmaceutical Intellectual Property in China
-
中国医药保健品进出口商会
China Chamber of Commerce for I / E of Medicines and Health Products
-
中国医药流通业现状及发展对策分析
Development of the Present Situation and the Strategy on Chinese Medicine Circulation Industry
-
开发中国医药卫生管理文献全文数据库的构想
Conception of Exploiting Complete Text Database of Medicine Sanitary Administration Literature in China